AVIR
AVIR clinical trials: Atea Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Atea Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 36
- Trials linked
- 33
- As lead sponsor
- 3
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
AVIR on the catalyst calendar · AVIR registry changes
- Primary completion Jun 18, 2026ActualPhase 3NCT06868264C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVAtea Pharmaceuticals, Inc. · HEPATITIS C VIRUS CHRONIC INFECTIONCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2026ActualPhase 1NCT07314346Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or MethadoneAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2026ActualPhase 1NCT06911320Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic FunctionAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07728487Study of AT-587 in Healthy SubjectsAtea Pharmaceuticals, Inc. · Hepatitis ERecruitingAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT07037277C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVAtea Pharmaceuticals, Inc. · HEPATITIS C VIRUS CHRONIC INFECTIONActive, not recruitingAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2026ActualPhase 1NCT07272889Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)Atea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2024ActualPhase 2NCT05904470A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCVAtea Pharmaceuticals, Inc. · Chronic Hepatitis C VirusCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 28, 2025ActualPhase 1NCT07007806Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/RuzasvirAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2, 2025ActualPhase 1NCT06921941Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and RosuvastatinAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2024ActualPhase 3NCT05629962SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19Atea Pharmaceuticals, Inc. · Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)CompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 25, 2024ActualPhase 1NCT06204679Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and RuzasvirAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2024ActualPhase 1NCT06356194Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/RuzasvirAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 23, 2024ActualPhase 1NCT05724693Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic FunctionAtea Pharmaceuticals, Inc. · Healthy VolunteerCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2024ActualPhase 1NCT05618314Study of AT-527 in Subjects With Normal and Impaired Renal FunctionAtea Pharmaceuticals, Inc. · Healthy VolunteerCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2023ActualPhase 2NCT05466240Study of AT-752 in Patients With Dengue InfectionAtea Pharmaceuticals, Inc. · Dengue FeverTerminatedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 19, 2023ActualPhase 1NCT05905497The Study of Bemnifosbuvir in Healthy Japanese SubjectsAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2023ActualPhase 1NCT05905484Study of Bemnifosbuvir on Cardiac Repolarization in Healthy SubjectsAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2023ActualPhase 1NCT05731843Drug-drug Interaction Study of Ruzasvir and BemnifosbuvirAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 16, 2023ActualPhase 1NCT05366439Study of AT-752 in Healthy Subjects in a Dengue Human Challenge ModelAtea Pharmaceuticals, Inc. · DengueTerminatedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 10, 2022ActualPhase 2NCT04396106Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital SettingAtea Pharmaceuticals, Inc. · COVID-19TerminatedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 23, 2022ActualPhase 1NCT05256732Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a MealAtea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2021ActualPhase 1NCT04722627Study of AT-752 in Healthy SubjectsAtea Pharmaceuticals, Inc. · DengueCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2022Sponsor estimatePhase 1/Phase 2NCT04309734Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected SubjectsAtea Pharmaceuticals, Inc. · Hepatitis CWithdrawnAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2021ActualPhase 1NCT05154123Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)Atea Pharmaceuticals, Inc. · Healthy Volunteer StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2021ActualPhase 1NCT05137626Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)Atea Pharmaceuticals, Inc. · Healthy Volunteers StudyCompletedAVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 11 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner